HealthcareMid capRs 8,877 crRs 17.1 cr traded a day
Close on 10 September 2026
557.70
−1.61%
52-week range69% of the way up
349.55649.35
Market cap
8,877 cr
P/E (TTM)
60.4×
industry 45×
EPS (TTM)
9.24
Revenue YoY
+53.0%
Q1 FY27
Profit YoY
+114.4%
Net margin
21.4%
+6.1pt vs a year ago
Growth trend
+7.8pt
vs last quarter’s YoY
1 month
-13.3%
Below 52w high
16.4%
RSI (14)
47
Daily swing
3.1%
average true range
Volume
0.8×
vs 20-day average
Traded
Rs 17 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Above the median
+17.9%
One-year return
Above the median
+37.3%
Return on capital employed
Top of the universe
33.2%
Debt to equity
Top of the universe
0.00×
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
145%
Revenue growth, year on year
latest reported quarter
+53.0%
Below the 52-week high
from the highest close of the year
-14.1%
1 week
−3.62%
1 month
−13.26%
3 months
+4.13%
6 months
+49.66%
1 year
+37.27%
The read
written from the numbers on this page
The evidence leans constructive7 supporting, 1 against, 1 worth knowing
Supporting
trading 18% above its 200-day average
up 37% over twelve months
matches profit that turns into cash, which has beaten the market by +2.73 points over 20 sessions across 9,184 past signals
9 of the scans it matches have a positive measured record
4 independent kinds of evidence agree today, which is uncommon
revenue grew 53% year on year in the quarter ending 30 June 2026
net margin has widened from 11.4% to 21.4% across four quarters
Against
priced at 60× earnings against an industry median of 45× — 35% above its peers
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
What would change this read: a close below 473, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Revenue rose 35.3% year on year, from Rs 177 cr to Rs 240 cr.
+35.3%Rs 177 crRs 240 cr
Profit rose year on year in all 4 of the last 4 quarters.
4
Operating cash flow was Rs 213 cr against Rs 147 cr of profit, which is 145% of it.
Rs 213 crRs 147 cr145%
Trading 17.9% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+17.9%
Up 37.3% over the past year.
+37.3%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching3
Net margin fell from 26.6% to 21.4%.
26.6%21.4%
Diagnostic Testing Services accounts for 94% of segment revenue, making it the largest reported segment.
Diagnostic Testing Services94%
Profit grew slower than revenue, +8.9% against +35.3%.
+8.9%+35.3%
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 6 of these 6 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
11 of 47 matched on 10 Sep
THYROCARE matches 11 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
segments and revenue mix, as the company reports them
THYROCARE reports 3 business segments. The largest is Diagnostic Testing Services at 94% of revenue in the quarter ending 30 June 2026. On these numbers this is effectively a single-segment business, so the group result and that segment’s result move together.
SegmentRevenueSharevs a year ago
Diagnostic Testing Services226 cr94.2%—
Imaging Services13 cr5.6%—
Others0 cr0.1%—
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.
Quality of the business
balance sheet as at 31 March 2026
Return on equity
25.1%
trailing profit over shareholders’ funds
Return on capital
33.2%
pre-tax profit over equity plus borrowings
Debt to equity
0.00×
0 cr borrowed against 586 cr of equity
Net debt
38 cr
cash exceeds borrowings
Cash conversion
145%
operating cash flow as a share of profit
Receivable days
33
how long customers take to pay
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 26 September 2024
36×
median 55×
69×
now 60×
THYROCARE trades at 60× trailing earnings, above its median of 55× over this window — 10% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
M&A filings were typically +0.18pt vs the market over the next 5 sessions (n=1,722) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 53% against the same quarter a year earlier
profit rose 114% year on year
revenue rose in 3 of the last 4 quarters
Going against it
net margin narrowed from 21.7% to 21.4%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
240
68
51
3.23
21.4%
Q4 FY26
31 Mar · consolidated
224
64
49
2.99
21.7%
Q3 FY26
31 Dec · consolidated
196
35
28
1.82
14.3%
Q3 FY25
31 Dec · consolidated
166
28
19
3.58
11.4%
Q2 FY25
30 Sep · consolidated
177
37
47
4.99
26.6%
Q1 FY25
30 Jun · consolidated
157
34
24
4.52
15.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-3.1%
Versus 200-day average+17.9%
Below 52-week high-14.1%
Above 52-week low+59.5%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)47.1
Higher closes in last 50 of 5
Six-month return+49.66%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.06%
Volume versus 20-day0.8x
Median daily turnoverRs 17.1 cr
Peers
Healthcare · 68 classified companies
THYROCARE trades at 60.4× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 35%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.